These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 7700652)

  • 1. Analysis of c-Myc and Max binding to the c-myc promoter: evidence that autosuppression occurs via an indirect mechanism.
    Buckle RS; Méchali M
    Oncogene; 1995 Mar; 10(6):1249-55. PubMed ID: 7700652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA binding of Myc/Max/Mad network complexes to oligonucleotides containing two E box elements: c-Myc/Max heterodimers do not bind DNA cooperatively.
    Vervoorts J; Lüscher B
    Biol Chem; 1999 Sep; 380(9):1121-6. PubMed ID: 10543451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA binding by N- and L-Myc proteins.
    Ma A; Moroy T; Collum R; Weintraub H; Alt FW; Blackwell TK
    Oncogene; 1993 Apr; 8(4):1093-8. PubMed ID: 8455937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.
    Amati B; Dalton S; Brooks MW; Littlewood TD; Evan GI; Land H
    Nature; 1992 Oct; 359(6394):423-6. PubMed ID: 1406955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Max and c-Myc/Max DNA-binding activities in cell extracts.
    Littlewood TD; Amati B; Land H; Evan GI
    Oncogene; 1992 Sep; 7(9):1783-92. PubMed ID: 1501888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Myc and Max interaction specificity with lambda repressor-HLH domain fusions.
    Marchetti A; Abril-Marti M; Illi B; Cesareni G; Nasi S
    J Mol Biol; 1995 May; 248(3):541-50. PubMed ID: 7752223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Myc and Max transregulate the mouse ornithine decarboxylase promoter through interaction with two downstream CACGTG motifs.
    Tobias KE; Shor J; Kahana C
    Oncogene; 1995 Nov; 11(9):1721-7. PubMed ID: 7478599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
    Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
    Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II.
    Bousset K; Oelgeschläger MH; Henriksson M; Schreek S; Burkhardt H; Litchfield DW; Lüscher-Firzlaff JM; Lüscher B
    Cell Mol Biol Res; 1994; 40(5-6):501-11. PubMed ID: 7735324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
    Västrik I; Mäkelä TP; Koskinen PJ; Saksela K; Alitalo K
    Princess Takamatsu Symp; 1991; 22():307-18. PubMed ID: 1668890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct visualization of the binding of c-Myc/Max heterodimeric b-HLH-LZ to E-box sequences on the hTERT promoter.
    Lebel R; McDuff FO; Lavigne P; Grandbois M
    Biochemistry; 2007 Sep; 46(36):10279-86. PubMed ID: 17705400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
    Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Myc does not require max for transcriptional activity in PC-12 cells.
    Ribon V; Leff T; Saltiel AR
    Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
    Austen M; Cerni C; Lüscher-Firzlaff JM; Lüscher B
    Oncogene; 1998 Jul; 17(4):511-20. PubMed ID: 9696045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
    Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
    Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.
    Raschella G; Romeo A; Negroni A; Pucci S; Dominici C; Castello MA; Bevilacqua P; Felsani A; Calabretta B
    Cancer Res; 1994 Apr; 54(8):2251-5. PubMed ID: 8174135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein complexes bearing myc-like antigenicity recognize two distinct DNA sequences.
    Negishi Y; Iguchi-Ariga SM; Ariga H
    Oncogene; 1992 Mar; 7(3):543-8. PubMed ID: 1549367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X; Giap C; Lazo JS; Prochownik EV
    Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.